ACPU
VRTX icon

Arrowgrass Capital Partners (US)’s Vertex Pharmaceuticals VRTX Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-48
Closed -$354K – 638
2016
Q4 		$354K Sell
48
-48
-50% -$3.91K ﹤0.01% 480
2016
Q3 		$837K Sell
96
-154
-62% -$14.6K 0.01% 371
2016
Q2 		$2.15M Sell
250
-125
-33% -$10.8K 0.02% 273
2016
Q1 		$2.98M Buy
375
+125
+50% +$11.3K 0.04% 235
2015
Q4 		$3.15M Buy
+250
New +$30.2K 0.04% 199

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s VRTX Position: Q4 2015 in Review

Arrowgrass Capital Partners (US) sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 199,200 shares — an estimated $24M sold.

Arrowgrass Capital Partners (US) first reported a position in VRTX in Q3 2013 and held it in 6 quarters. The position peaked at $21.4M in Q3 2013. 517 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 199,200 Vertex Pharmaceuticals shares in Q4 2015, an estimated $24M.
  • Arrowgrass Capital Partners (US) first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Arrowgrass Capital Partners (US)'s Vertex Pharmaceuticals position peaked at $21.4M in Q3 2013.
  • 517 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2015, filed 16 Feb 2016.